Abstract：Objective: To study and analyze the therapeutic effect of specific immunity on allergic rhinitis with asthma and whether it is safe to use it widely in clinic. Methods: All patients were simple random grouping divided into two groups: immune group and symptomatic group. They were treated with standardized house dust mite allergen preparations and symptomatic drugs respectively. The severity of the disease and the use of drugs were evaluated before the start of the study, one year, two years and three years after the treatment. The adverse symptoms during the whole study were recorded in detail. Results: The nasal and asthmatic symptom scores and drug use scores of the two groups showed a significant downward trend (P<0.05), and the data of the symptomatic group were significantly higher than those of the immune group (P<0.05); the probability of adverse symptoms in the immune group was much lower than that in the symptomatic group (P<0.05). Conclusion: Specific immunotherapy for allergic rhinitis with asthma is better than symptomatic drugs, so it is more suitable for clinical use.
2019, Vol. 25 
冀公网安备13080202000677号